MARKET

GERN

GERN

Geron Corp
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.415
-0.035
-2.41%
Opening 11:21 05/16 EDT
OPEN
1.440
PREV CLOSE
1.450
HIGH
1.475
LOW
1.400
VOLUME
344.36K
TURNOVER
309.32K
52 WEEK HIGH
2.230
52 WEEK LOW
0.9899
MARKET CAP
534.09M
P/E (TTM)
-3.9415
1D
5D
1M
3M
1Y
5Y
--Needham Trims Geron's Price Target to $2 From $3, Buy Rating Kept
MT Newswires · 6d ago
Geron (GERN) Reports Q1 Loss, Tops Revenue Estimates
Geron (GERN) delivered earnings and revenue surprises of 18.18% and 23%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 6d ago
Geron GAAP EPS of -$0.09 beats by $0.01, revenue of $0.12M beats by $0.02M
Geron press release (NASDAQ:GERN): Q1 GAAP EPS of -$0.09 beats by $0.01. Revenue of $0.12M (-14.3% Y/Y) beats by $0.02M. Under current planning assumptions, the Company projects its existing capital
Seekingalpha · 05/09 20:14
Geron Q1 EPS $(0.09), Same YoY, Sales $123.00K Down From $137.00K YoY
Geron (NASDAQ:GERN) reported quarterly losses of $(0.09) per share. This is unchanged from the same period last year. The company reported $123.00 thousand in sales this quarter. This is a 10.22 percent decrease over
Benzinga · 05/09 20:12
Notable earnings after Monday's close
ADES, AGM, AIV, AKBA, ALCO, ALTO, AMC, AMPH, AMWL, ANGI, APPF, APTO, ARCT, AROC, ASLE, ASRT, ATER, AVIR, AZTA, BATL, BHF, BLFS, BLI, BLNK, BODY, OTCPK:BOWFF, BRMK, BRT, BW, BWXT,
Seekingalpha · 05/08 21:35
Geron Q1 2022 Earnings Preview
Geron (NASDAQ:GERN) is scheduled to announce Q1 earnings results on Monday, May 9th, after market close. The consensus EPS Estimate is -$0.10 (-11.1% Y/Y) and the consensus Revenue Estimate is
Seekingalpha · 05/08 21:35
Shareholders in Geron (NASDAQ:GERN) are in the red if they invested five years ago
It is a pleasure to report that the Geron Corporation ( NASDAQ:GERN ) is up 32% in the last quarter. But if you look at...
Simply Wall St. · 05/01 12:39
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif., April 21, 2022--Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 505,800 shares of Geron common stock as inducements to newly hired employees in connection with...
Business Wire · 04/21 20:30
More
No Data
Learn about the latest financial forecast of GERN. Analyze the recent business situations of Geron Corp through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

40.00%Strong Buy
60.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average GERN stock price target is 4.000 with a high estimate of 7.00 and a low estimate of 2.000.
High7.00
Average4.000
Low2.000
Current 1.410
EPS
Actual
Estimate
-0.08-0.06-0.04-0.02
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 200
Institutional Holdings: 134.15M
% Owned: 41.44%
Shares Outstanding: 377.45M
TypeInstitutionsShares
Increased
45
2.87M
New
17
438.10K
Decreased
39
5.58M
Sold Out
12
229.85K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.23%
Pharmaceuticals & Medical Research
+1.02%
Key Executives
Chairman/President/Chief Executive Officer/Director
John Scarlett
Chief Financial Officer/Executive Vice President - Finance/Treasurer
Olivia Bloom
Chief Operating Officer/Executive Vice President
Andrew Grethlein
Executive Vice President/Secretary
Stephen Rosenfield
Executive Vice President
Anil Kapur
Executive Vice President
Melissa Kelly Behrs
Executive Vice President
Edward Koval
Executive Vice President
Aleksandra Rizo
Lead Director/Independent Director
Karin Eastham
Independent Director
Dawn Bir
Independent Director
V. Bryan Lawlis
Independent Director
Susan Molineaux
Independent Director
Elizabeth O'Farrell
Independent Director
Robert Spiegel
No Data
No Data
About GERN
Geron Corporation is a late-stage clinical biopharmaceutical company, which is focused on the development and commercialization of imetelstat, a therapeutic for hematologic myeloid malignancies. The Company operates through a single segment, which is engaged in the development of therapeutic products for oncology. Imetelstat is a lipid conjugated 13-mer oligonucleotide that is designed to be complementary to and bind with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity. The clinical studies of imetelstat include IMerge, a Phase III trial in lower risk myelodysplastic syndromes (MDS) and IMbark, a Phase II trial in Intermediate- II or High-risk myelofibrosis. Its IMpactMF is an ongoing Phase III clinical trial in refractory myelofibrosis (MF).

Webull offers kinds of Geron Corporation stock information, including NASDAQ:GERN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GERN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GERN stock methods without spending real money on the virtual paper trading platform.